Online Training Modules for Your Organization's Team

Designed for professionals at all levels to learn about Health Economic & Outcomes Research (HEOR) concepts and trends. Select relevant modules for your team, which can also be combined with customized in-person programs.

Empower your team with interactive online training

  • Engage colleagues in HEOR discussions
  • Interpret HEOR studies
  • Communicate HEOR data more effectively
  • Understand how analyses are used by decision makers
  • Become better consumers of pharmacoeconomic literature

demo 5 Min Overview Video


  • Define pharmacoeconomic research, and how it's used
  • Identify five ways a medication can be considered "cost-effective”
  • Distinguish among types of costs (direct medical, direct non-medical, indirect, intangible)
  • Describe types of outcomes (e.g., surrogate vs final; economic, clinical, patient-reported) and how they are incorporated into cost-effectiveness analyses
  • Recognize how to interpret a cost-effectiveness plane
  • Describe various study perspectives
  • Identify the importance of sensitivity analysis

  • Identify differences among various pharmacoeconomic methodologies, such as cost-of-illness analysis, cost-minimization analysis, cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis
  • Calculate the incremental cost-effectiveness for one medication over another
  • Describe how utility values are used to calculate a quality-adjusted life year
  • Explain how to interpret data plotted on a cost-effectiveness grid
  • Discuss the difference between average cost-effectiveness ratios and incremental cost-effectiveness ratios
  • Describe the advantages of using cost-effectiveness acceptability curves

  • Define patient-reported outcomes (PROs) and when they should be used
  • Identify types of instruments used to measure PROs, including generic and disease-specific tools
  • Describe examples of commonly used PRO instruments, including the SF-36 Health Survey and the EQ-5D
  • Discuss the importance of measuring what is important to the patient
  • List examples of PRO label claims
  • Outline recommendations in the FDA PRO Guidance
  • Explain how a PRO instrument can be considered valid and reliable
  • Identify additional resources for PRO assessments
  • Explain the role of patient-reported outcomes assessment in the evaluation of health care products and services

  • Clarify definitions and policy issues, and why RWE has received so much attention from various stakeholders
  • Define and distinguish between real-world-data (RWD) and real-world evidence (RWE)
  • Describe different types of RWE studies including associated advantages and disadvantages
  • Differentiate observational study designs including cohort, case control, and pragmatic trials
  • Discuss statistical techniques used in observational research such as propensity score matching and multi-level modeling
  • Compare and contrast various tools available for evaluating observational studies

  • Outline definitions and uses of primary, secondary, and tertiary data sources.
  • Describe common sources and examples of observational data (registries, surveys, administrative claims and electronic medical records databases) used to generate RWE, including their advantages and limitations
  • Identify common sources and examples of costs and outcomes data used to populate pharmacoeconomic analyses, including their advantages and limitations

  • Define performance-based risk-sharing agreements and why they are becoming so popular
  • Describe key characteristics of performance-based risk-sharing (PBRS) agreements
  • Discuss use of agreements in the US, including types and therapeutic areas
  • Identify good practice recommendations issued by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) PBRS Task Force
  • Outline specific examples of performance-based risk-sharing (PBRS) agreements
  • List benefits, challenges, and potential barriers for performance-based risk-sharing agreements

  • Define components included in budget impact analyses
  • Discuss ISPOR Principles of Good Practice for Budget Impact Analysis
  • Describe examples of published budget impact analyses
  • Identify key questions that are raised about budget impact analyses
  • Outline differences between budget impact and pharmacoeconomic analyses
  • Discuss ways to best communicate budget impact models with end users

  • Identify the steps in building a decision tree
  • Indicate how the data elements entered into a decision tree should be analyzed
  • Apply the fundamental concepts learned to build a decision tree using Excel software
  • Outline results from a case study on a cost-effectiveness plane
  • Interpret findings from the decision analysis based on willingness-to-pay principles
  • Recognize how to calculate incremental cost-effectiveness ratios (ICERs) for 3+ alternatives

  • Differentiate between decision trees and Markov models
  • Describe Markov model structures & how patients transition between health states
  • Identify temporary, tunneling, and absorbing states in a model
  • Discuss how to assign costs & utility values to health states that patients accrue over time
  • Distinguish between a cohort model and a patient-level model
  • Apply Markov modeling concepts to construct a model using Excel software

  • Define value frameworks & identify their limitations
  • Recognize that high drug prices demand justification from payers
  • Outline initiatives by professional societies to create value frameworks
  • Recognize the impact of the Institute for Clinical & Economic Review (ICER) recommendations
  • Describe pricing strategies & alternative payment models to manage costly pharmaceuticals
  • Indicate challenges with current value-based pricing models


Each Module Contains

  • Learning objectives
  • One-hour videos presented in approximately 15-minute segments
  • Interactive video questions
  • PDF handout of the presentation slides
  • Self-assessment questions
  • Interactive games

Request to sample a Module

Pharmacy continuing education credit is not available for the online modules at this time.

For more information

Lynne Mascarella, MEd
Coordinator, Training and Operations
Center for Health Outcomes & PharmacoEconomic Research (HOPE Center)